Psoriasis

NEW ORLEANS — Phase 2b clinical trial results of Takeda Pharmaceuticals’ novel tyrosine kinase 2 inhibitor found significantly greater skin clearance in study patients compared with placebo, according to a presentation here.

Systemic medications for the treatment of pediatric psoriasis failed to increase serious infection risk, according to a study.

Spesolimab exhibited rapid control of generalized pustular psoriasis flare symptoms in as little as 24 hours and up to 12 weeks, according to a study.

Patients with palmoplantar plaque-type psoriasis had significantly improved signs and symptoms of disease when treated with a topical halobetasol propionate and tazarotene emulsion, according to a study.

A calcipotriene and betamethasone foam formulation was well tolerated and efficacious in treating plaque psoriasis in patients with skin of color, according to a study.

Once-daily halobetasol propionate 0.01% and tazarotene 0.045% fixed-combination lotion stands out as a favorable treatment option amid topical therapies deemed unsatisfactory by psoriasis patients, according to a systematic review.

Water-free, lipid-based spray formulations of calcipotriol were efficacious and safe in psoriasis vulgaris treatment and could potentially increase treatment adherence among patients, according to a study.

The lipid-lowering drug proprotein convertase subtilisin/kexin type 9 was associated with an increase in psoriasis risk, according to a study.

Therapeutic options for psoriasis have grown exponentially over the past few decades with scores of topical, oral and biologic drugs now available.

Psoriasis is not only a disease that impacts patients physically, with scars and red patchy skin, but it also impacts patients emotionally. Patients’ mental health often suffer due to the anxieties of living with the condition. In response, Arcutis Biotherapeutics has launched an educational campaign, Expose Psoriasis, with the intention of reducing the emotional toll of psoriasis.